Posted by Michael Wonder on 30 Jun 2020
First adalimumab biosimilar gains approval in Japan
30 June 2020 - Fujifilm Kyowa Kirin Biologics said it has received Japanese regulatory approval to manufacture and market the first adalimumab biosimilar in the island country.
The company said the approval was received 29 June for the product, which was identified as Hulio. It references AbbVie’s Humira.
The product is indicated for rheumatoid arthritis, psoriasis vulgaris, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, entero-behcet’s disease, Crohn disease, and polyarticular-course juvenile idiopathic arthritis.
